Alzheimer’s Disease: The Past, Present, and Future of a Globally Progressive Disease

Abstract

Alzheimer's disease (AD) is a significant 21st-century public health challenge. This article delves into AD's neurodegenerative complexities, highlighting cognitive decline, memory impairment, and societal burdens. Mechanistically, protein misfolding, amyloid-beta (Aβ) pathway abnormalities, and genetic/environmental factors are discussed. The pivotal amyloid hypothesis is dissected, focusing on Aβ aggregation's role in synaptic dysfunction and neurodegeneration. The review showcases promising therapeutic strategies, including anti-amyloid antibodies and β/γ-secretase inhibitors targeting Aβ production. Notably, the FDA-approved Lecanemab signifies a breakthrough, slowing disease progression. Anti-Tau therapies' emergence is highlighted, addressing late-stage intervention. Tau aggregation blockers and anti-Tau antibodies offer potential against intracellular tau pathology. The review underscores collaborative efforts to uncover AD's secrets and pave the way for memory preservation.

Abstract of "Alzheimer’s Disease: The Past, Present, and Future of a Globally Progressive Disease" by Bhuvanasai Vejandla, Sarah Savani, Rohith Appalaneni et al., https://doi.org/10.7759/cureus.51705, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.